Navigation Links
Grant from Smith & Nephew Helps Continue Educational Activities for Podiatric Surgeons
Date:10/30/2013

LONDON, Oct. 30, 2013 /PRNewswire/ -- Smith & Nephew (NYSE: SNN;LSE:SN), the global medical technology business, today announced its new educational relationship with the recently formed American Academy of Foot and Ankle Osteosynthesis (AAFAO). Through this relationship, a grant from Smith & Nephew will be used to fund AAFAO's continuing education courses for internal fixation of the foot and ankle.

(Logo - http://photos.prnewswire.com/prnh/20131030/CL06769LOGO )

"For more than 150 years, we have supported healthcare professionals with innovative technologies, life-changing treatments and ongoing medical education," says Mark Waugh, Vice President for Smith & Nephew's Global Extremities & Limb Restoration Strategic Business Unit. "We are extremely proud to be working with an organization like AAFAO which shares our commitment to surgeon education."  

In addition to the grant, Smith and Nephew will also provide a new location for the training courses in its new Innovation Centre. Located in Memphis, TN, the Centre is a world-class medical training facility dedicated to the advancement of surgical technology and expertise. Within the two-story, 62,000-square-foot Centre is a 140-seat auditorium, five integrated conference rooms and 15 lab stations – each with full cadaveric capability, OR lighting and state-of-the-art operating tables.  

The first AAFAO course being offered at the new facility will be "Comprehensive Course of Internal Fixation for Reconstructive Surgery and Trauma of the Foot & Ankle." Information and registration for this course is available on the AAFAO website – www.aafao.org.

About AAFAO
The American Academy of Foot and Ankle Osteosynthesis is a new educational organization dedicated to the training of podiatric residents in the techniques and skills of skeletal fixation, trauma and reconstructive surgery of the foot and ankle.

About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has around 11,000 employees and a presence in more than 90 countries. Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.

Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.  

Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office. All Trademarks acknowledged.


'/>"/>
SOURCE Smith & Nephew
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Northwest Bio Awarded $5.5 Million German Government Grant
3. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
4. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
5. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
6. Broad Patent Protection Granted for iBio Immunomodulator
7. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
8. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
9. QRxPharma Granted Additional US Patent on MoxDuo®
10. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
11. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):